Skip to main content

Table 5 Recommendations on the use of calcitonin gene-related peptide monoclonal antibodies for the prevention of episodic and chronic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Setting

Drug

Recommendation

Quality of evidence

Strength of the recommendation

Migraine prevention in patients with episodic migraine

Eptinezumab 1000 mg quarterly

Suggested

LOW

↑? Weak

Erenumab 70 mg monthly

Recommended

HIGH

↑↑ Strong

Erenumab 140 mg monthly

Recommended

MEDIUM

↑↑Strong

Fremanezumab 225 mg monthly

Recommended

HIGH

↑↑ Strong

Fremanezumab 675 mg quarterly

Recommended

MEDIUM

↑↑Strong

Galcanezumab 240 mg loading dose + 120 mg monthly

Recommended

HIGH

↑↑ Strong

Galcanezumab 240 mg monthly

Recommended

HIGH

↑↑ Strong

Migraine prevention in patients with chronic migraine

Erenumab 70 mg monthly

Recommended

MEDIUM

↑↑Strong

Erenumab 140 mg monthly

Recommended

MEDIUM

↑↑Strong

Fremanezumab 675 mg quarterly

Recommended

MEDIUM

↑↑Strong

Fremanezumab 675 mg loading dose + 225 mg monthly

Recommended

HIGH

↑↑ Strong

Galcanezumab 240 mg loading dose + 120 mg monthly

Recommended

MEDIUM

↑↑Strong

Galcanezumab 240 mg monthly

Recommended

MEDIUM

↑↑Strong

  1. Symbols depict the strength of the recommendation according to the GRADE system. The quality of evidence for the Galcanezumab study was changed from medium to high